Zipalertinib Placebo Tablets is a film-coated tablet that does not contain the active ingredient, zipalertinib., Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Zipalertinib, Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung
TAS6417-302
Phase 3 small_molecule active
Quick answer
Zipalertinib Placebo Tablets is a film-coated tablet that does not contain the active ingredient, zipalertinib., Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Zipalertinib, Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung for Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations is a Phase 3 program (small_molecule) at Taiho Pharma Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Taiho Pharma Netherlands B.V.
- Indication
- Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active